MeiraGTx is a biotechnology company based in New York, New York, specializing in the development of genetic medicine therapies. Situated in the heart of New York City, MeiraGTx focuses on advancing clinical-stage treatments designed to address serious and often life-threatening diseases. The company leverages cutting-edge gene therapy technologies to explore new medical frontiers and improve patient outcomes.
As a biotechnology company, MeiraGTx is involved in multiple aspects of genetic medicine, including research, development, and clinical testing. Its efforts are centered on creating innovative solutions that have the potential to provide long-lasting benefits and possibly curative effects for individuals with rare and complex conditions. The company’s operations encompass the rigorous processes required to bring experimental treatments from the laboratory to clinical trials.
Located at 450 E 29th St, MeiraGTx maintains a strong presence in the vibrant New York biotech community. Its team comprises scientists, researchers, and industry professionals who collaborate to push the boundaries of gene therapy. By integrating advanced biotechnology tools with clinical expertise, MeiraGTx aims to contribute to the evolving landscape of medical science.
With a focus on precision medicine, MeiraGTx represents an important player in the biotechnology sector within New York. The company’s commitment to developing genetic treatments highlights the growing role of gene therapy in addressing unmet medical needs. For those seeking specialized biotechnological innovation in the New York area, MeiraGTx offers a dedicated and scientifically driven approach.


































